Korro Bio, Inc.
Korro Bio, Inc. (KRRO): 10 pipeline candidates · ~21 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
21.1 months
0% dilution
Lead: Phase 1/Phase 2
10 candidates
N/A
10 buys · 3 sells (180d)
A transparent, data-derived signal for Korro Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$159.4M
Cash
$61.7M
Quarterly Burn
$16.1M
Runway
21.1 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| aatd program | Preclinical |
| als program | Preclinical |
| krro-110 | Phase 1/Phase 2 |
| krro-121 | Phase 1/Phase 2 |
| longevity | Preclinical |
| undisclosed als program | Preclinical |
| undisclosed cardiometabolic program 1 | Preclinical |
| undisclosed cardiometabolic program 2 | Preclinical |
| undisclosed pain program | Preclinical |
| undisclosed rare metabolic disorder program | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
95
Total value held
$106.6M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 1,538,296 | $17.4M |
| balyasny asset management l.p. | 1,040,054 | $11.8M |
| affinity asset advisors, llc | 706,904 | $8.0M |
| vanguard capital management llc | 621,826 | $7.0M |
| adar1 capital management, llc | 540,054 | $6.1M |
| blackrock, inc. | 460,006 | $5.2M |
| driehaus capital management llc | 450,045 | $5.1M |
| tcg crossover management, llc | 416,301 | $4.7M |
| siren, l.l.c. | 347,718 | $3.9M |
| 72 investment holdings, llc | 276,831 | $3.1M |
Showing top 10 of 95 institutional holders of Korro Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Korro Bio, Inc.'s pipeline?
Korro Bio, Inc. (KRRO) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Korro Bio, Inc.'s lead drug candidate?
Korro Bio, Inc.'s most advanced tracked candidate is aatd program (Preclinical) for Alpha-1 antitrypsin deficiency (AATD).
What is Korro Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Korro Bio, Inc. has approximately 21.1 months of cash runway.
What is Korro Bio, Inc.'s market capitalization?
Korro Bio, Inc.'s market capitalization is approximately $159.4M.
Who is the CEO of Korro Bio, Inc.?
Dr. Ram Aiyar MBA, Ph.D. is the chief executive officer of Korro Bio, Inc. (KRRO).
Get the full picture on Korro Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.